Product Pipeline Overview

GenVec’s AdenoVerse™  technology platform is extremely flexible and can be customized to achieve targeted or broad delivery of genes or antigens for a wide variety of applications, including cell therapy, regenerative medicine, cancer therapeutics, vaccines, and antivirals. The pipeline summary to follow reflects a few of the ways that our technology platform can be applied to develop innovative therapeutics and vaccines that deliver on the promise of gene-based medicine.

GenVec Pipeline Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 Approved
Hearing Loss [Novartis]
Discovery Phase completed
Pre-Clinical Phase completed
Phase 1 in progress
Phase 2 not started
Phase 3 not started
Approved not started
Cancer [TheraBiologics]
Discovery Phase completed
Pre-Clinical Phase in progress
Phase 1 not started
Phase 2 not started
Phase 3 not started
Approved not started
PEC Delivery and Gene Editing
[Washington University in St. Louis]
Discovery Phase in progress
Pre-Clinical Phase not started
Phase 1 not started
Phase 2 not started
Phase 3 not started
Approved not started
Herpes Simplex Virus 2 (HSV-2)
Discovery Phase completed
Pre-Clinical Phase in progress
Phase 1 not started
Phase 2 not started
Phase 3 not started
Approved not started
Respiratory Syncytial Virus (RSV)
Discovery Phase completed
Pre-Clinical Phase in progress
Phase 1 not started
Phase 2 not started
Phase 3 not started
Approved not started
Malaria [LMIV, NMRC]
Discovery Phase in progress
Pre-Clinical Phase not started
Phase 1 not started
Phase 2 not started
Phase 3 not started
Approved not started
Foot & Mouth Disease [Merial, DHS]
Discovery Phase completed
Pre-Clinical Phase completed
Phase 1 completed
Phase 2 completed
Phase 3 completed
Approved in progress